Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,843.29
(
0.65%
)
News Focus
News Focus
Post# of 518944
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Steady_T

Send PM Follow Ignore
Followers 170
Posts 23215
Boards Moderated 1
Alias Born 12/09/2004

Steady_T

Member Level

Re: Pazzo1212 post# 468634

Friday, 08/30/2024 4:47:31 PM

Friday, August 30, 2024 4:47:31 PM

Post# of 518944
Thanks for bringing that to the board.

A little more awareness of the company amongst the professionals.

Pre-specified SIGMAR1 Gene Variant Analysis in Phase IIb/III Trial Supports Precision Medicine Mechanism of Action (MoA) with Improved Treatment Effect of Blarcamesine in Early Alzheimer Disease
Marwan N. Sabbagh 1, Juan Carlos Lopez-Talavera 2, Kun Jin 2, William Robert Chezem 2, Christopher U. Missling 2
1Barrow Neurological Institute - Phoenix (United States), 2Anavex Life Sciences - New York (United States)

Nunc est Bibendum

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News